Roche's Xeloda Gains Approval For Adjuvant Colon Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves capecitabine for adjuvant treatment in patients with Dukes' C colon cancer. Roche is positioning Xeloda as an oral alternative to intravenous 5-fluorouracil/leucovorin-based chemotherapy.
You may also be interested in...
Roche's Xeloda Shows Significant Survival Benefit In Pancreatic Cancer
Combo therapy of Xeloda plus gemcitabine shows median survival of 7.4 months versus six months with Gemzar alone.
Roche's Xeloda Shows Significant Survival Benefit In Pancreatic Cancer
Combo therapy of Xeloda plus gemcitabine shows median survival of 7.4 months versus six months with Gemzar alone.
Xeloda Growth Due To Off-Label Adjuvant Colorectal Cancer Use, Roche Says
The increase in Xeloda prescribing is also “partly due to some change in the reimbursement patterns,” Pharma Strategic Marketing Head Sabbah says. U.S. sales for the first quarter were up 74% to approximately $51 mil.